Literature DB >> 11091179

Harnessing graft-versus-malignancy: non-myeloablative preparative regimens for allogeneic haematopoietic transplantation, an evolving strategy for adoptive immunotherapy.

R Champlin1, I Khouri, A Shimoni, J Gajewski, S Kornblau, J Molldrem, N Ueno, S Giralt, P Anderlini.   

Abstract

Entities:  

Mesh:

Year:  2000        PMID: 11091179     DOI: 10.1046/j.1365-2141.2000.02196.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


× No keyword cloud information.
  30 in total

1.  Reduced intensity conditioning is superior to nonmyeloablative conditioning for older chronic myelogenous leukemia patients undergoing hematopoietic cell transplant during the tyrosine kinase inhibitor era.

Authors:  Erica Warlick; Kwang Woo Ahn; Tanya L Pedersen; Andrew Artz; Marcos de Lima; Michael Pulsipher; Gorgun Akpek; Mahmoud Aljurf; Jean-Yves Cahn; Mitchell Cairo; Yi-Bin Chen; Brenda Cooper; Abhinav Deol; Sergio Giralt; Vikas Gupta; H Jean Khoury; Holbrook Kohrt; Hillard M Lazarus; Ian Lewis; Richard Olsson; Joseph Pidala; Bipin N Savani; Matthew Seftel; Gerard Socié; Martin Tallman; Celaettin Ustun; Ravi Vij; Lars Vindeløv; Daniel Weisdorf
Journal:  Blood       Date:  2012-03-09       Impact factor: 22.113

Review 2.  Novel approaches in allogeneic stem cell transplantation.

Authors:  Esperanza B Papadopoulos; Ann A Jakubowski
Journal:  Curr Oncol Rep       Date:  2006-09       Impact factor: 5.075

3.  The war on cancer: a report from the front lines.

Authors:  Gavin Melmed
Journal:  Proc (Bayl Univ Med Cent)       Date:  2006-10

4.  Low-intensity transplant regimens facilitate recruitment of donor-specific regulatory T cells that promote hematopoietic engraftment.

Authors:  Ling Weng; Julian Dyson; Francesco Dazzi
Journal:  Proc Natl Acad Sci U S A       Date:  2007-05-09       Impact factor: 11.205

5.  Similar transplantation outcomes for acute myeloid leukemia and myelodysplastic syndrome patients with haploidentical versus 10/10 human leukocyte antigen-matched unrelated and related donors.

Authors:  Antonio Di Stasi; Denái R Milton; L M Poon; Amir Hamdi; Gabriela Rondon; Julianne Chen; Sai R Pingali; Marina Konopleva; Piyanuch Kongtim; Amin Alousi; Muzaffar H Qazilbash; Sairah Ahmed; Qaiser Bashir; Gheath Al-atrash; Betul Oran; Chitra M Hosing; Partow Kebriaei; Uday Popat; Elizabeth J Shpall; Dean A Lee; Marcos de Lima; Katayoun Rezvani; Issa F Khouri; Richard E Champlin; Stefan O Ciurea
Journal:  Biol Blood Marrow Transplant       Date:  2014-09-28       Impact factor: 5.742

6.  Effect of age on outcome of reduced-intensity hematopoietic cell transplantation for older patients with acute myeloid leukemia in first complete remission or with myelodysplastic syndrome.

Authors:  Brian L McClune; Daniel J Weisdorf; Tanya L Pedersen; Gisela Tunes da Silva; Martin S Tallman; Jorge Sierra; John Dipersio; Armand Keating; Robert P Gale; Biju George; Vikas Gupta; Theresa Hahn; Luis Isola; Madan Jagasia; Hillard Lazarus; David Marks; Richard Maziarz; Edmund K Waller; Chris Bredeson; Sergio Giralt
Journal:  J Clin Oncol       Date:  2010-03-08       Impact factor: 44.544

7.  Allogeneic stem cell transplantation for chronic myeloid leukemia resistant to tyrosine kinase inhibitors.

Authors:  Richard Champlin; Elias Jabbour; Partow Kebriaei; Paolo Anderlini; Borje Andersson; Marcos de Lima
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2011-04-28

Review 8.  Minor histocompatibility antigens--targets of graft versus leukemia responses.

Authors:  Stanley R Riddell; M Murata; S Bryant; E H Warren
Journal:  Int J Hematol       Date:  2002-08       Impact factor: 2.490

Review 9.  Treatment of chronic myeloid leukaemia: lessons and challenges.

Authors:  John M Goldman
Journal:  Int J Hematol       Date:  2002-08       Impact factor: 2.490

10.  Survival after cord blood transplantation from unrelated donor as a second hematopoietic stem cell transplantation for recurrent pediatric acute myeloid leukemia.

Authors:  M Oda; K Isoyama; E Ito; M Inoue; M Tsuchida; H Kigasawa; K Kato; S Kato
Journal:  Int J Hematol       Date:  2009-03-18       Impact factor: 2.490

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.